CHOSA team to participate at ASCO and present phase II data from the iCIP study
CHOSA has submitted an abstract presenting data on the first predictive biomarker for cisplatin and LiPlaCis in metastatic breast cancer to ASCO. The CHOSA team will participate in the ASCO conference as part of its business development efforts and engage in meetings with interested parties.Heavily pretreated late-stage breast cancer patients of any subtype represent a huge treatment challenge. Cisplatin may work in selected patients but is often disqualified because of toxicity. LiPlaCis® is a liposomal formulation of cisplatin in development utilizing the sPLA2-triggered targeted release